MedTrace Logo

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

NCT00370214 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3515

Last updated 2013-05-17

No results posted yet for this study

Summary

The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.

Conditions

  • Pulmonary Hypertension

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Michael D. McGoon, M.D. · Mayo Clinic - Rochester, Minnesota

  • David B. Badesch, M.D. · University of Colorado, Denver

  • Robyn J. Barst, M.D. · Columbia University

  • Raymond Benza, M.D. · University of Alabama at Birmingham

  • Gregory Elliott, M.D. · LDS Hospital

  • Harrison Farber, M.D. · Boston Medical Center

  • Adaani Frost, M.D. · Baylor College of Medicine

  • Abby Krichman, RRT · Duke University Pulmonary Vascular Disease Center

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370214 on ClinicalTrials.gov